Alaunos Therapeutics (TCRT) Research & Development (2011 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Research & Development came in at $427000.0 in Q1 2026, up 23.05% YoY from $347000.0 in Q1 2025, and up 18.28% on a QoQ basis from $361000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Research & Development (2011 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 16 years of Research & Development data on file, last reported at $427000.0 in Q1 2026.
- Quarterly Research & Development rose 23.05% year-over-year to $427000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 146.92% YoY) and the FY2025 annual result came in at $1.4 million, up 276.52% from the prior year.
- Research & Development advanced to $427000.0 in Q1 2026, from $361000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $7.9 million in Q3 2022 to a low of -$86000.0 in Q4 2024.
- A 5-year average of $2.6 million and a median of $469000.0 in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development plunged 109.22% — and 2025, when it jumped 519.77%.
- Tracing TCRT's Research & Development over 5 years: stood at $5.6 million in 2022, then tumbled by 83.36% to $933000.0 in 2023, then tumbled by 109.22% to -$86000.0 in 2024, then jumped by 519.77% to $361000.0 in 2025, then rose by 18.28% to $427000.0 in 2026.
- The last three Research & Development figures came in at $427000.0 (Q1 2026), $361000.0 (Q4 2025), and $469000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | 388,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 427,000.00 |
| Dec 31, 2025 | 361,000.00 |
| Sep 30, 2025 | 469,000.00 |
| Jun 30, 2025 | 185,000.00 |
| Mar 31, 2025 | 347,000.00 |
| Dec 31, 2024 | -86,000.00 |
| Sep 30, 2024 | 143,000.00 |
| Jun 30, 2024 | 180,000.00 |
| Mar 31, 2024 | 126,000.00 |
| Dec 31, 2023 | 933,000.00 |
| Sep 30, 2023 | 3.66 Mn |
| Jun 30, 2023 | 5.19 Mn |
| Mar 31, 2023 | 6.50 Mn |
| Dec 31, 2022 | 5.61 Mn |
| Sep 30, 2022 | 7.89 Mn |
| Jun 30, 2022 | 5.94 Mn |
| Mar 31, 2022 | 5.58 Mn |
| Dec 31, 2021 | 8.22 Mn |
| Sep 30, 2021 | 14.52 Mn |
| Jun 30, 2021 | 13.57 Mn |